B-cell lymphomas that harbor the MYD88L265P mutation form a complex with phosphorylated Bruton’s tyrosine kinase (BTK) and are responsive to BTK inhibition. The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.